Compare Tango Therapeutics Inc. (TNGX) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs ProShares Ultra Semiconductors — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while ProShares Ultra Semiconductors trades at $80.64 (market cap $2.80B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and ProShares Ultra Semiconductors is more actively traded (764,825 versus 3,438,781). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and ProShares Ultra Semiconductors for 30 Days on average.
| TNGX | USD | |
|---|---|---|
Market Cap | $3.74B | $2.80B |
Volume | 3,438,781 | 764,825 |
Sector | Health | Leveraged / Inverse |
52-Week High | $32.90 | $113.53 |
52-Week Low | $7.50 | $43.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
USD stock trades at $91.26 with a modest 0.26% daily gain, showing neutral momentum amid bearish technical signals. The company declared a $0.13 dividend for H2-2026, payable September 29, 2026. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support sits at $90 and resistance at $93.
Fundamental data remains limited with key ratios unavailable, requiring deeper financial review. The stock faces headwinds from bearish technical trends but maintains dividend distribution. Investment appeal hinges on upcoming financial disclosures and market sentiment shifts amid current neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
